Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)
Patients with an acute exacerbation of Relapsing-Remitting Multiple Sclerosis or with
Clinically Isolated Syndrome receive either one single infusion of Nanocort or three daily
infusions of SoluMedrol. Main objective is to assess the occurrence of new
gadolinium-enhanced T1-weighted lesions at week 8 vs week 1 after treatment.
Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis
Eyegate Pharmaceuticals, Inc.
The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with
dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery
System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with
non-infectious anterior segment uveitis.
Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
The purpose of this study is to evaluate the effectiveness of the modified Conjunctival
Allergen Challenge (CAC) and observe how the produced allergic inflammation reacts to
treatment with a proven ocular anti-inflammatory medication,
Prednisolone, assessed by the following measures:
- Ocular itching
- Conjunctival redness
Silencing Inflammatory Activity by Injecting Nanocort in Patients at Risk for Atherosclerotic Disease
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 1/Phase 2
Cardiovascular disease(CVD) is the leading cause of morbidity and mortality in developed
nations. CVD is primarily caused by atherosclerosis, a systemic disease characterized by
lipid deposition in the subendothelial space with a concomitant, low-grade inflammatory
reaction.(Fuster, Moreno et al. 2005) To date, most therapeutic interventions aimed at
lowering CVD have thus far focused on modulating lipid levels, either lowering LDLc or
increasing HDLc levels. Yet, since the introduction of statins 20 years ago, there have been
few breakthroughs in the treatment of this disease. A promising strategy to reduce CVD is to
directly target inflammation at the level of the vessel wall.(van Leuven, van Wijk et al.;
Libby 2002) A potential drawback of anti-inflammatory strategies pertains to the thin line
between inhibiting 'inappropriate' inflammation versus inducing immuno-suppression.
Therefore, continuous low dosed anti-inflammatory drugs have great potential as novel
treatment strategies. In the present project, the investigators propose to inject liposomal
glucocorticoids intravenously in patients with an increased risk of atherosclerotic disease
aiming to reduce vessel wall inflammation.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.